Forest Keeps Up Lexapro Detailing Pressure In Face Of Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest's antidepressant continues to be the most detailed product in the class, the company says; aggressive detailing is increasingly important with Forest's loss of exclusivity for Celexa and Lilly's launch of Cymbalta. Forest expects Lexapro to be approved for social anxiety and panic disorders early this year.